Healthcare is testing its guardrails.
What’s happening: The New York Times profiled telehealth company MEDVi, touting it as a “one-person billion-dollar company” powered by AI.
Red flags. Framed as a breakout DTC platform for GLP-1s—outsourcing prescribing, pharmacy, and fulfillment—its growth tactics were largely overlooked.
Applying a “move fast, break things” playbook to patient acquisition, MEDVi allegedly relies on questionable, potentially illegal tactics, including:
- Using AI-generated before-and-after photos and altered testimonials
- Promoting treatments using fake or misrepresented doctors
- Marketing unapproved oral GLP-1 products without proven efficacy, drawing FDA warnings over misleading claims
Fact check. AI isn’t driving MEDVi; demand for DIY Health is. As consumer-led care expands, predatory, AI-driven marketing puts people at risk, undermining efforts to legitimize new interventions and emerging distribution models.
Looking ahead: Access is improving, but trust is eroding. In a system where anyone can launch a healthcare storefront, credibility—not convenience—is what’s for sale.
